← Back to Search

Treatment for Interstitial Lung Disease (PFFR Trial)

N/A
Waitlist Available
Led By Catherine A Spino, ScD
Research Sponsored by Pulmonary Fibrosis Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 55 months
Awards & highlights

Summary

The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000 patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US. The Registry is targeting enrollment of approximately 60% of the 2,000 ILD participants to have idiopathic pulmonary fibrosis (IPF). The aim of the Registry is to create a cohort of well-characterized patients with interstitial lung disease (ILD) for participation in retrospective and prospective research

Eligible Conditions
  • Interstitial Lung Disease
  • Idiopathic Pulmonary Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 55 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 55 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Body Weight Changes
Change in % predicted FVC

Find a Location

Who is running the clinical trial?

Pulmonary Fibrosis FoundationLead Sponsor
7 Previous Clinical Trials
10,613 Total Patients Enrolled
University of MichiganOTHER
1,833 Previous Clinical Trials
6,421,124 Total Patients Enrolled
Catherine A Spino, ScDPrincipal InvestigatorUniversity of Michigan
~213 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top